(Q38229303)

31 August 2017

title

Nivolumab: a review of its use in patients with malignant melanoma (English)

1 reference

31 August 2017

1

Emma D Deeks

1 reference

31 August 2017

publication date

1 July 2014

1 reference

31 August 2017

1 reference

31 August 2017

volume

74

1 reference

31 August 2017

issue

11

1 reference

31 August 2017

page(s)

1233-1239

1 reference

Current and future trials of targeted therapies in cutaneous melanoma

31 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0234-4

The intersection of immune-directed and molecularly targeted therapy in advanced melanoma: where we have been, are, and will be.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0234-4

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0234-4

Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0234-4

PD-1 identifies the patient-specific CD8⁺ tumor-reactive repertoire infiltrating human tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0234-4

Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0234-4

Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0234-4

Nivolumab plus ipilimumab in advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0234-4

PD-1 as a potential target in cancer therapy

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25022950

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Nivolumab: promising survival signal coupled with limited toxicity raises expectations

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25022950

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Melanoma: from melanocyte to genetic alterations and clinical options

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25022950

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S40265-014-0234-4

1 reference

Dimensions Publication ID

31 August 2017

1044508550

0 references

1 reference